Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Atossa Therapeutics Inc

ATOS ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$2.60

▲ +1.56%

Market Cap $25.95M · Vol 31.06K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$25.95M

Micro Cap

Div Yield

N/A

EPS Growth

-6.44%

YoY

RSI (14)

61.01

Momentum

Beta

1.31

vs Market

52W High

$19.28

86.51% below

52W Low

$1.72

51.16% above

Volume

31.06K

Avg 22.35K

P/B

1.94

Price-to-book

ROE

N/A

Return on equity

Free Float

98.05%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Atossa Therapeutics Inc (ATOS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ATOS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+10.17%

+15.04%

-49.51%

-38.10%

YTD

-70.62%

-77.78%

-80.33%

-94.62%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-34,770,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-56.06% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.94
P/FCF	N/A
EPS Growth	-6.44%
Outstanding Shares	9.98M

Technical Indicators

50-Day SMA	$2.49
200-Day SMA	$6.34
RSI (14)	61.01
Beta	1.31
52-Week High	$19.28
52-Week Low	$1.72

Volume Today	31.06K
Avg Daily Volume (30D)	22.35K
Relative Volume	1.39x
Volatility (10D)	51.24
Volatility (30D)	67.13
Free Float	98.05%

Analyst Consensus

BUY

Current Price $2.60

Mean Target $17.00

52W Low$1.72 52W High$19.28

Current

Target

$1.72 $19.28

Current Analyst target

+553.85% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG002NCD954

ISINUS04962H7044

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).